Prevalence of Pneumonyssoides caninum infection in dogs in Sweden

A prospective study of 474 dogs, 145 cats, and 66 wild red foxes submitted for necropsy to the Departments of Pathology at the National Veterinary Institute and the Swedish University of Agricultural Sciences, Uppsala, Sweden, was conducted to examine for the presence of Pneumonyssoides caninum, the canine nasal mite. Pneumonyssoides caninum (P. caninum) was found in 95 (20%) of the dogs but in none of the cats or foxes. The median number of P. caninum mites per infected dog was 13 (range, 1 to 250). Dogs older than 3 years of age were more often infected with P. caninum than younger dogs, and large-breed dogs were more often infected than small-breed dogs. No sex predisposition was found.

Download Full-text

Correlation of Clinical, Radiographic, and Surgical Localization of Intervertebral Disc Extrusion in Small-Breed Dogs: A Prospective Study of 50 Cases

Veterinary Surgery ◽

10.1111/j.1532-950x.1998.tb00105.x ◽

1998 ◽

Vol 27 (2) ◽

pp. 105-111 ◽

Cited By ~ 39

Author(s):

KURT S. SCHULZ ◽

MICHAEL WALKER ◽

MARTHA MOON ◽

DON WALDRON ◽

MARGARET SLATER ◽

...

Keyword(s):

Intervertebral Disc ◽

Prospective Study ◽

A Prospective Study ◽

Disc Extrusion ◽

Small Breed

Download Full-text

Ifosfamide or trofosfamide for intraocular lymphoma: Long-term results of a prospective study

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.18524 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 18524-18524

Author(s):

E. Thiel ◽

K. Jahnke ◽

J. Bechrakis ◽

T. Wagner ◽

L. Fischer ◽

...

Keyword(s):

Prospective Study ◽

Aqueous Humor ◽

Progression Free Survival ◽

Median Number ◽

Long Term Results ◽

Intraocular Lymphoma ◽

Who Grade ◽

Intravenous Hydration ◽

A Prospective Study

18524 Background: The prognosis of intraocular lymphoma (IOL) is poor, and the optimal treatment has not yet been defined. In a prospective study, ifosfamide (IFO) or trofosfamide (TRO) have been assessed for treating IOL. Here, long-term results are presented. Patients and Methods: Patients with histologically proven isolated IOL were included. The median age of the patients was 74 years (range 46–83 years); 4 patients had a newly diagnosed disease and 6 a relapse. IFO was administered intravenously at a dose of 1.5 - 2.0 g/m2/day for 3 days every three weeks. TRO was given at a dose of 150 or 400 mg/day (continuous or intermittent administration) to 4 patients considered unable to receive intensive intravenous hydration. IFO, TRO and their active 4-hydroxy (4-OH) metabolites were measured in aqueous humor of 9 patients. Results: The median number of IFO courses was 6 (range 2–8), the median duration of TRO therapy was 8.5 months (range 6–18 months). All patients responded. Toxicity > WHO grade 2 was: anemia grade 2 in 2 patients, leukopenia grade 2–3 in 2 patients, nausea/vomiting grade 2 in 2 patients, thrombopenia and cystitis grade 2 in 1 patient each. Thus far, three patients each have developed cerebral and ocular relapse. Median progression-free survival from the study treatment was 9.5 months (range 6 - 24+ months), median overall survival was 15.5 months (range 6–34 months). Both patients retreated with IFO on ocular relapse responded. In 6 of 6 patients, 4-OH metabolites were detected in the aqueous humor immediately after IFO infusion with an aqueous/serum ratio of 0.19–0.54. Three to 16 hours after ingestion of TRO, 4-OH metabolites could be detected in one of 3 patients. Conclusions: Response rate of IOL to IFO or TRO is high with a tolerable toxicity even in elderly patients. However, long-term remissions are infrequent. Combining IFO/TRO with other cytostatics seems reasonable to improve long-term disease control. No significant financial relationships to disclose.

Download Full-text